ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2018

Dec 12, 2018

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Living Cell Technologies Limited
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Laurie Hunter
Date of last notice	19 March 2008

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Hunter 2005 Living Trust2,176,911 ordinary fully paid sharesHunter Capital Defined Benefit PensionPlan468,750 ordinary fully paid shares
Date of change	13 December 2018
No. of securities held prior to change	Total of 2,645,661 ordinary fully paidshares
Class	Unlisted Options
Number acquired	600,000 unlisted options
Number disposed	nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation	Exercisable at $0.0487 per option andexpiring on 13 December 2022.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	Hunter 2005 Living Trust2,176,911 ordinary fully paid shares600,000 unlisted optionsHunter Capital Defined Benefit PensionPlan468,750 ordinary fully paid shares
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	Following shareholder approval at theannual general meeting held on 15November 2018, Mr Hunter has beenissued600,000optionsfornilconsideration with an exercise price of$0.0487 with an expiry date of 13December 2022. These options compriseacomponentoftheDirectors’remuneration.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 317] intentionally omitted <==

----- Start of picture text ----- Detail of contract N/ANature of interestName of registered holder(if issued securities)Date of changeNo. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changedInterest acquiredInterest disposedValue/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuationInterest after change----- End of picture text -----

Part 3 –[+] Closed period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3